talquetamab Talvey
Selected indexed studies
- Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. (N Engl J Med, 2022) [PMID:36507686]
- Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma. (N Engl J Med, 2025) [PMID:39778168]
- Talquetamab (Talvey) for multiple myeloma. (Med Lett Drugs Ther, 2023) [PMID:37682687]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy. (2025) pubmed
- Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. (2022) pubmed
- Talquetamab in Multiple Myeloma: Efficacy, Safety, and Future Directions. (2025) pubmed
- Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma. (2025) pubmed
- Talquetamab: First Approval. (2023) pubmed
- Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study. (2025) pubmed
- Antibodies to watch in 2024. (2024) pubmed
- Talquetamab (Talvey) for multiple myeloma. (2023) pubmed
- PMID:40758794 (2025) pubmed
- PMID:40294187 (2025) pubmed